Cynvenio Launches New Tumor Genomics Product

Westlake Villlage-based Cynvenio Biosystems said yesterday that it has launched a new program, aimed at sequencing patient tumors from whole blood. The new program is aimed at cancer research centers, and allows those centers to analyze the genome profile of cancer tumors, based on whole blood samples. Cyvenio said the new service is already being used by The Mayo Clinic Cancer Center in Rochester, Minnesota and the Norris Comprehensive Cancer Center, part of the Keck School of Medicine at the University of Southern California. Cynvenio said its new LiquidBiopsy program is a complement to traditional, tissue biopsy testing, and is being used to measure a patient's response to treatments in a painless and risk-free way.